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Abstract
CXCR1, a classic GPCR that binds IL-8, plays a key role in neutrophil activation and migration by activating phospholipase C
(PLC)b through Ga15 and Gai which generates diacylglycerol and inositol phosphates (IPs). In this study, two conserved
amino acid residues of CXCR1 on the transmembrane domain (TM) 3 and TM6, Leu128
3.43 (L128) and Val247
6.40 (V247),
respectively, were selectively substituted with other amino acids to investigate the role of these conserved residues in
CXCR1 activation. Although two selective mutants on Leu128, Leu128Ala (L128A) and Leu128Arg (L128R), demonstrated
high binding affinity to IL-8, they were not capable of coupling to G proteins and consequently lost the functional response
of the receptors. By contrast, among the four mutants at residue Val247 (TM6.40), replacing Val247 with Ala (V247A) and Asn
(V247N) led to constitutive activation of mutant receptors when cotransfected with Ga15. The V247N mutant also
constitutively activated the Gai protein. These results indicate that L128 on TM3.43 is involved in G protein coupling and
receptor activation but is unimportant for ligand binding. On the other hand, V247 on TM6.40 plays a critical role in
maintaining the receptor in the inactive state, and the substitution of V247 impaired the receptor constraint and stabilized
an active conformation. Functionally, there was an increase in chemotaxis in response to IL-8 in cells expressing V247A and
V247N. Our findings indicate that Leu128
3.43 and Val247
6.40 are critical for G protein coupling and activation of signaling
effectors, providing a valuable insight into the mechanism of CXCR1 activation.
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Introduction
Interleukin-8 (IL-8) is a member of the CXC-chemokine family
and is a potent chemotactic factor for neutrophils [1] and natural
killer cells [2]. IL-8 activates these cells via two related chemokine
receptors CXCR1 and CXCR2 [3,4,5,6]. Although both recep-
tors bind IL-8, CXCR1 and CXCR2 have distinct physiological
activities. CXCR1 is generally more resistant to desensitization
and downregulation [3], and is also important in the generation of
antimicrobial responses and in the respiratory burst upon
neutrophil activation [3]. Inflammatory diseases such as chronic
obstructive pulmonary disease (COPD), asthma, inflammatory
bowel diseases, and Crohn’s disease are thought to be exacerbated
by neutrophils. As such, targeting CXCR1 using structural and
biochemical means to design specific antagonists is a promising
therapeutic strategy to modulate the activity of the receptor to
combat these diseases [7,8,9,10,11,12]. Additionally, because
CXCR1 promotes IL-8-mediated tumor growth, CXCR1 block-
ade can selectively target and eliminate human breast cancer stem
cells [13], androgen-independent prostate cancer [14,15], and
malignant melanoma [16,17], highlighting IL-8/CXCR1 signal-
ing as a possible therapeutic intervention point in targeting the
tumor microenvironment [18].
CXCR1 is a member of GPCRs that feature the characteristic
seven transmembrane domains. Upon activation, CXCR1 couples
to both pertussis toxin-sensitive Gai and pertussis toxin-resistant
Ga15 [19] to mediate CXCR1-activated signal transduction
pathways. These pathways are necessary for the induction of
inflammatory responses or for more subtle regulation of cellular
functions such as phosphoinositide (PI)3 hydrolysis, intracellular
Ca
2+ mobilization, and chemotaxis [20]. Several critical amino
acid residues and functional motif/domains of the human CXCR1
have been identified, including the N terminal region responsible
for determining the receptor subtype selectivity [21] and receptor
activation [22], as well as the C terminal tail which is involved in
IL-8-induced internalization [23], migration and activation [4,20].
Some residues of CXCR1 involved in agonist binding, signaling
activation and receptor internalization have been identified
[24,25,26,27]. Despite these substantial advances, however, the
exact mechanism of chemokine receptor activation is still largely
unknown.
GPCRs possess similar structures that consist of seven trans-
membrane helices containing well-conserved sequence motifs,
which suggests that they are probably activated by a common
mechanism [28,29,30]. Among the seven TMs, TM3 and TM6
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play an important role for the transition to their fully activated
state [29,31,32] and in interactions between the receptor and G
proteins [33]. Analysis of crystal structure of rhodopsin and
agonist-bound human adenosine A2A receptor suggests that
activation of GPCRs is due to disruption of key interhelical
contacts [33,34]. This activation involves the rotation of TM3 and
TM6 domains and affects the conformational structure of G
protein-interacting cytoplasmic loops of the receptor, thereby
uncovering previously masked G protein-binding sites on the
intracellular loops [31].
Within the structure of GPCR, Leu128
3.43 (superscript in this
form indicates Ballesteros–Weinstein numbering for conserved
GPCR residues), located at the region near the second intracel-
lular loop in TM3, is highly conserved (over 70%) [35] which
suggests that this residue may play an important structural and
functional role in other GPCRs as well. Based on CXCR1
homology with the crystal structure of rhodopsin, Val 247 is
predicted to lie near the cytoplasmic end of TM6, which is
oriented towards several highly conserved amino acids in TM2,
TM3 and TM7. As rhodopsin and other type A GPCRs may share
a common mechanism of receptor activation [28,29,30], we
investigated the role of L128 in TM3.43 and V247 in TM6.40 in
G protein coupling and signaling properties of constitutively active
forms of the human CXCR1.
It is noteworthy that IL-8 and its specific receptor CXCR1 are
identified in humans but are not found in the traditional rodent
model organisms. As a consequence, we utilized well established
cell models which were transfected with CXCR1 and other related
cellular components to study the functions of IL-8 and CXCR1 as
well as the mechanisms involved in receptor activation by IL-8. In
this study, we generated selective mutations on two conserved
amino acid residues of CXCR1 on TM3 and TM6, Leu128
3.43
(L128) and Val247
6.40 (V247), respectively. We analyzed their
features including receptor expression, and ligand binding. The
capacity of Ga15 and Gai to be coupled by CXCR1 mutants is
determined by measuring downstream signaling transduction
pathways such as PLCb-IP3 production and cAMP production.
To test for functional consequence of activation by CXCR1
mutants, we performed chemotaxis assays with cells that express
CXCR1 and its mutants.
Materials and Methods
Construction of Expression Vectors and Site-directed
Mutagenesis
Wild type (WT) human CXCR1 cloned into pSFFVNneo vector
was provided as a gift from Professor Ingrid Schraufstatter at the
La Jolla Institute for Experimental Medicine. After digestion with
EcoRI, wild type human CXCR1 fragment was subcloned into the
pSG5 vector. Oligonucleotides for site-directed mutagenesis were
designed to yield several different amino acid substitutions and
were synthesized by GIBCO BRL. CXCR1 mutations were
generated with the Transformer mutagenesis kit (Clontech, Palo
Alto, CA) and were confirmed by Big Dye Terminator Cycle
Sequencing (Perkin Elmer) of the final construct. Plasmid DNA for
transient transfection was purified with the EndoFree Plasmid
Maxi Kit from Qiagen.
Transient Transfection
COS-7 cells and human embryonic kidney 293 cells (HEK293
cells) from the American Type Culture Collection (ATCC,
Rockville, MD) were maintained at 37uC in humidified air
containing 5% CO2 in DMEM with 10% FBS. Cells were grown
to 60,80% confluency prior to transient transfection. Transfec-
tion was performed using LipofectAMINE reagent (GIBCO BRL,
Gaithersburg, MD) according to the manufacturer’s instruction.
COS-7 cells were incubated with the transfection complex for
5 hrs at 37uC. After removal of the transfection medium, the cells
were incubated in DMEM with 10% FCS overnight.
Flow Cytometry
HEK 293 cells were transfected with either pSG5 plasmid, or
CXCR1 WT or mutants. After 48 hr, cells were dissociated and
fixed with 4% paraformaldehyde. Cells were then washed three
times with cold staining buffer before incubation with mouse anti-
human CD128 FITC (CXCR1) from BD Pharmingen (Cat#
555939) (San Diego, CA) on ice for 20 min. Cells were washed
three times and resuspended in 0.5 ml of staining buffer. Stained
cell samples were analyzed by flow cytometry [36].
Confocal microscopy
COS-7 cells or TSA-201 cells (# 96121229 from Sigma-
Aldrich, St Louis, MO) were transfected with either pSG5
plasmid, or CXCR1 WT or mutants. After 24 hr, cells were fixed
with 4% paraformaldehyde followed by blocking with 1% BSA in
HBSS. Cells were incubated with primary antibody (mouse anti
human CD128a (CXCR1)) from BD Pharmingen (5A12 clone)
(San Diego, CA) at 4uC overnight. After washing three times, the
cells were incubated with the secondary antibody (Alexa Fluor
488, goat anti-mouse IgG(H+L) from Invitrogen, CA, or DyLight
549-conjugated goat anti-mouse IgG(H+L) from Jackson Immu-
noResearch Laboratories, Inc., PA) at RT for 1 hr and
counterstained with Dapi. Expression of CXCR1 or the mutants
was observed using confocal microscope.
IL-8 Binding Assay
COS-7 cells were plated in 12-well plates at a density of
1.6610
5 cells/ml of DMEM/10% FCS and incubated overnight.
The cells were transfected as described before. In brief, the cells
were transfected with 0.7 mg DNA plus 2.5 ml of LipofectAMINE
reagent and 5 ml Plus Reagent (total transfection volume was
0.5 ml/well). After 48 hrs from the start of transfection, transfect-
ed cells were washed in the binding buffer (HBSS medium
containing 0.5% BSA and 25 mM HEPES buffer). The cells were
then incubated for 2 hr at 4uC. The final concentration of
125I-IL-
8 in the 0.5 ml/well (for 12-well plate) of medium was 0.07 nM
(0.05 mCi). The range of unlabeled IL-8 concentrations in the
binding assays was 0.1–300 nM [0, 0.1, 0.3, 1, 3, 10, 30, 100,
300 nM]. The nonspecific
125I-IL-8 binding was determined by
incubating cells with
125I-IL-8 in the presence of 250 nM of cold
IL-8. In experiments designed to test the maximal binding of
125I-
IL-8 to CXCR1 WT and mutants, unlabelled IL-8 was not added.
After washing three times with 2 ml of ice-cold binding buffer, the
cells were lysed in 0.5 ml of 1 N NaOH and the lysates were
counted using a scintillation counter. The data were curve fitted
and affinity constant (Kd) and maximum total binding (Bmax) were
calculated using GraphPad Prism (San Diego, CA). All experi-
ments were carried out in triplicate.
Inositol Phosphate (IP) Assays
For IP assay, COS-7 cells were plated in 24-well plates with a
density of 1610
5 cells per well the day before transfection. The
cells were cotransfected with 0.3 mg CXCR1 plasmid DNA (or its
mutants) and 0.3 mgG a15 plus 1.5 ml LipofectAMINE reagent and
0.5 ml Plus reagent. In experiments of cotransfection with WT
CXCR1 or its mutants, COS-7 cells were cotransfected with equal
CXCR1 Mutants with Constitutive Activity
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encoding Gai2 and PLCb2 were generous gifts from Dr. Kozasa at
the University of Illinois at Chicago. Plasmids encoding Gb1 and
Gc2 were kindly provided by Guthrie Research Institute, PA.
(Sayre, PA). 24 hr after transfection, cells were incubated with
inositol-free medium containing 2 ml/ml myo-[2-
3H]inositol
(Dupont-NEN, Boston, MA) in the absence or presence of
100 ng/ml pertussis toxin (PTX) as indicated for 18 hr. At 48 hr
from the start of transfection, cells were washed with assay buffer
[Hank’s balanced salt solution, 0.5% (w/v) crystalline bovine
serum albumin, 20 mM HEPES-NaOH, pH7.4]. IP production
was measured by incubating the cells for 1 hr at 37uC in 0.2 ml
assay buffer containing 10 mM LiCl in the presence or absence of
40 nM IL-8. Perchloric acid was added to each well and samples
were then neutralized with a solution of 0.72 M KOH and 0.6 M
KHCO3 before being centrifuged. Total IP was measured using
Dowex AG1-X8 anion exchange column chromatography (Bio-
Rad, Richmond, CA). All assays were performed in triplicate, on
at least 3 separate occasions with different batches of cells, and
always included control cells transfected with WT CXCR1. Data
were analyzed using GraphPad Prism (San Diego, CA) and
expressed as fold-increase over basal conditions in cells cotrans-
fected with WT CXCR1 and Ga15 plasmid.
Intracellular calcium mobilization assays
COS-7 cells were transiently transfected with CXCR1 WT or
V247N mutant. Preparation of dye-loading solutions of BD
calcium assay kits (BD Biosciences, Rockville, MD.) were
performed and fluorescence was measured as described in the
manual.
cAMP assay
How CXCR1 WT and V247N mutant would affect cAMP
formation was assessed in both COS-7 and HEK-293 cell-derived
TSA-201 cells. Both cell lines are useful to demonstrate GPCR-
triggered cAMP accumulation. However, unlike COS-7 cells, type
II adenylyl cyclase I in TSA-201 cells is not stimulated by free bc
subunits released from activated Gai protein which can inhibit
cAMP accumulation when transfected with Gai-coupled receptors
such as CXCR1 [37,38]. COS-7 cells and HEK293 cell-derived
TSA-201 cells were maintained in DMEM, and supplemented
with 10% FBS. COS-7 cells were transiently transfected with
0.2 mg of CXCR1 or CXCR1 mutant V247N as well as Gai2,
Gb1, and Gc2. TSA-201 cells were grown to 50% confluency in
DMEM/10% FBS on 24-well plates and were transfected using
lipofectaMINE with 0.2 mg of each DNA encoding human LH
receptor, or CXCR1 WT, or V247N mutant per well. 48 hours
after transfection, COS-7 cells or TSA-201 cells were washed once
with 16HBSS/0.1% BSA pre-warmed buffer. The cells were
incubated with 16HBSS/0.1% BSA containing 0.5 mM IBMX
for 30 min followed by treatment of the cells with the same
medium containing either forskolin (10 mM) or hCG (10
27 M) in
the presence or absence of IL-8 (40 nM) for another 30 min. Then
the treatment buffer was aspirated and the reaction stopped with
0.85 ml of 5% cold perchloric acid (PCA). It was left for 10 min
before the transfer of 0.8 ml to the 12675 glass tubes with 0.18 ml
of 36neutralization buffer (0.72 M KOH, 0.6 M KHCO3). The
samples were vortexed and centrifuged at 2,5006 g for 5 min.
cAMP levels were measured with a RIA Kit (Biomedical
Technologies Inc., Stoughton, MA) according to the manufactur-
er’s instructions. Data are shown as mean 6 SEM for three assays
with each condition performed in triplicate.
Chemotaxis assay
IL-8 stimulated chemotaxis through CXCR1 and CXCR1
mutants was assessed using a 48-well microchemotaxis chamber
technique (Neuro-Probe, Gaithersburg, MD). CXCR1 or CXCR1
mutant V247A or V247N as well as Gai,G b,G c, and PLCb2 was
transiently transfected in HEK293 cells. 24 hours after transfec-
tion, the cells were serum-starved in 0.5% FCS-containing
medium for another 24 h. The cells were then trypsinized, treated
with trypsin inhibitor (Sigma), resuspended in BSA medium at
5610
5 cells/mL, and incubated for 2 h at 37uC. To the bottom
wells 28 ml of either 100 ng/ml IL-8 or the solution without IL-8
(control group) were added as chemoattractant. For some
indicated wells, cells were pretreated with 200 ng/ml of pertussis
toxin for 10 min before being added to the upper chamber for
chemotaxis assay. For all the migration assays, 50 mlo f1 610
6
cells/mL were loaded into the upper chamber fitted with a 10-mm
pored membrane (Nucleopore, Corning Costar, Acton, MA)
coated with 50 mg/mL rat collagen type 1 (Collaborative
Biomedical Products, Bedford, MA) for 4 h. This allowed cells
to migrate towards the underside of the insert filter. Cells that did
not migrate through the pores and therefore remained on the
upper side of the filter membrane were gently removed with a
cotton swab. Cells on the lower side of the insert filter were quickly
fixed with 5% glutaraldehyde solution for 10 minutes and then
stained with 1% Crystal Violet in 2% ethanol for 20 minutes. The
cells that adhered to the lower surface of the membranes were
counted microscopically at 4006magnification. The chemotactic
activity was expressed as a chemotactic index, calculated as the
number of cells that migrated in response to IL-8, divided by the
number of cells that migrated toward the negative control (dilution
buffer without IL-8 for control cells). Statistical analysis was
performed using Student’s t test.
Results
Construction and expression of CXCR1 mutants
To define the G protein coupling and signaling properties of
constitutively active forms of the human CXCR1, we generated 7
different mutations at 2 residues that correspond to known sites of
activating mutations in TM3 and TM6 of rhodopsin, the human
LHR, and several other GPCRs [39,40,41,42,43,44,45]. Three
amino acid substitutions of the L128 (L128A, L128Q, and L128R)
and four amino acid substitutions of the V247 (V247A, V247F,
V247N and V247Y) in the chemokine receptor CXCR1 were
made using mutagenesis to analyze their functional role (Fig. 1).
Flow cytometry (Fig. 2) utilized to monitor the expression of
CXCR1 and its mutants showed that WT and mutant CXCR1
were expressed on transfected cells (Fig. 2 A, B). The expression
pattern was confirmed also by confocal imaging (data not shown).
Ligand binding assay of CXCR1 mutants
We performed ligand binding assay determine if the CXCR1
mutants are capable of binding to specific ligands, and to assess the
maximum binding number (Fig. 3A) and affinity constant (Kd)o f
the mutant receptors (Fig. 3 B and C). Mock (transfected with
pSG5 vector) did not show
125I IL-8 ligand binding, suggesting
that there is no endogenous IL-8 receptor such as CXCR1
expression in COS-7 cells (Fig. 3A). Among mutants detected,
V247F barely bound to
125I IL-8 ligand whereas all other CXCR1
mutants showed specific binding to
125I IL-8 ligand (Fig. 3 A, B
and C). The results of ligand binding assays for CXCR1 mutants
are summarized in Table 1. The affinity constant (Kd)o fW T
CXCR1 for IL-8 obtained by ligand binding assay in transfected
COS-7 cells was 4.87610
29 M, which was similar to those
CXCR1 Mutants with Constitutive Activity
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neutrophils [46,47]. It was noteworthy that mutants L128Q and
V247N showed Kd values similar to the WT, while other mutants
including L128A, L128R, V247A and V247Y, demonstrated
increased Kd values (Table 1). The altered Kd values from the
mutants suggested that the receptor exists in multiple conforma-
tions.
Specific mutation on TM6 (V247) of CXCR1 leads to Ga15
coupling and constitutively activated inositol phosphate
accumulation
Ga15 protein is expressed exclusively in hematopoietic cells of
myeloid lineage on which CXCR1 is expressed. The Ga15
activates the phospholipase Cb isoform in a PTX-resistant manner
and causes inositol phosphate accumulation [48]. For these
studies, we used COS-7 cells and HEK-293 cells to take advantage
of the lack of endogenous CXCR1 expression with the added
convenience of transfection with high efficiency. Both cell lines
have been well established as cell models to study CXCR1 and its
signaling [19,25,26]. In this study, IL-8 treatment of cells
transfected with WT CXCR1 alone did not stimulate IP formation
as shown in Fig. 4A. This suggested that CXCR1 was coupled to
neither Gaq nor Gas present in COS-7 cells. In fact, none of the
CXCR1 mutants could stimulate PLCb unless they were
coexpressed with Ga15. Cotransfection with mock pSG5 and
Ga15 had no effect on IP formation in response to IL-8, suggesting
that there was no endogenous CXCR1 present in COS-7 cells
(Fig. 4A). COS-7 cells did not have any measurable PLCb
response to IL-8 in the absence of Ga15 expression, indicating that
there was insufficient PLCb2 or PLCb3 expressed for a Gai-
dependent, bc-mediated IL-8 response. As shown in Fig. 4A, the
PLCb response could be reconstituted by expressing Ga15.
To examine the role of L128 and V247 in Ga15 coupling,
CXCR1 mutants were cotransfected with Ga15 in COS-7 cells.
While mutant L128Q behaved like WT with regard to PLC
activation, mutant L128A and L128R were not effective in IP
accumulation in response to IL-8 (Fig. 4B). This suggested that
introduction of A or R for L128 abolished IP accumulating
property, implying the important role of L128 in Ga15 coupling. It
is noteworthy that two mutants, V247A and V247N were able to
elevate basal levels of IP in transfected COS-7 cells by 196% and
272%, respectively, in the absence of IL-8. IL-8-independent
activation of the phospholipase C signaling pathway indicated that
both V247A and V247N are constitutively active mutants coupled
to Ga15 resulting in PLCb activation and IP accumulation.
To assess whether V247 mutants display unique features and to
determine the degree of IP production between A and N mutants,
two constitutively active CXCR1 mutants were cotransfected with
Ga15 in COS-7 cells followed by treatment with varying
concentrations of IL-8 (Fig. 5A). In the absence of IL-8, both
V247A and V247N were coupled to Ga15 and constitutively
activated the IP accumulation. In response to IL-8, however, the
degree of IP production was dissimilar between A and N.
Although both V247A and V247N stimulated IP accumulation
in response to IL-8 in a dose-dependent manner in COS-7 cells,
the maximum IP accumulation of V247A in response to IL-8 was
distinct from that of V247N. The V247A showed maximum IP
accumulation similar to WT in response to 40 nM of IL-8,
Figure 1. Two-dimensional diagram of human CXCR1 receptor. The positions of the residues (Leucine 128 and Valine 247) that were targeted
for mutagenesis in TM3 and TM6 of the CXCR1 are indicated by gray and black filled circles respectively. The putative disulfide bridge, formed by
Cys110/Cys 187 is indicated by ‘‘S-S’’.
doi:10.1371/journal.pone.0042765.g001
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was much higher than WT (Fig. 5A). As expected, intracellular
calcium changes were more robust in V247N transfected cells than
CXCR1 WT transfected cells (Fig. 5B).
Ability of CXCR1 WT and mutants to activate Gai
CXCR1 could activate bc subunits of endogenous Gai/o
proteins independently of their coupling to recombinant Ga15
protein. To investigate the mechanism by which CXCR1 signaling
is activated, CXCR1 WT or mutants were cotransfected into
COS-7 cells with Gai2,G b1,G c2 and PLCb2. This five-
component cotransfection system (Gai2-G b1-G c2 - PLCb2) has
been successfully applied to investigate IL-8 signaling pathways in
COS-7 cells in a previous study [19]. In this cotransfection system,
Gai2 activation in response to IL-8 leads to the release of Gbc
subunits from Gai2, which results in PLCb2 activation and
subsequent IP accumulation [19]. As shown in Fig. 6A, mutants
L128A, L128Q, as well as V247A, V247N and V247Y stimulated
IP accumulation in response to IL-8, much like the WT CXCR1
counterpart. Furthermore, PTX, a specific inhibitor of Gai, totally
suppressed Gai activation and subsequent IP accumulation,
suggesting that CXCR1 and its mutants investigated here are
indeed coupled to Gai2. Thus, IP accumulation could be achieved
via the PTX-insensitive Ga15 pathway or the PTX-sensitive Gai2
pathway as described above. Interestingly, L128R and V247F
failed to have any effect on IP formation in response to IL-8 in
transfected COS-7 cells (data not shown). Among all mutants
detected, V247F bound the most poorly to IL-8. Because this
mutant showed low expression as indicated by flow cytometry
(Fig. 2A and B), it is likely that binding to IL-8 was low due to
fewer mutant receptor expressed on fewer cells (Fig. 3A). Because
L128R has high specific binding to IL-8, it is likely that the
conformational changes of L128R impaired coupling to Gai2
whereas the failure of V247F to respond to IL-8 resulted from the
lack of ligand binding.
The coupling of CXCR1 and its mutants to Gai2 was further
supported by data shown in Fig. 6B. COS-7 cells were
cotransfected with equal amounts of encoding Gaqi5 (qi5) and
the WT CXCR1 or its mutants. The chimeric G protein, Gaqi5,
contains main structure of Gaq and the last five C-terminal amino
acids of Gaq were replaced with the corresponding amino acids
from Gai2. Mutation of the last five C-terminal amino acids is
sufficient to completely switch receptor coupling selectivity and
enable Gai/o-coupled GPCR signaling through phospholipase Cb
(PLCb). As such, a classical Gaq-mediated output becomes
indicative of receptor coupling to Gai/o [49,50]. Transient
expression of Gaqi5 in the COS-7 cell line facilitated the activation
of CXCR1 WT and V247N mutant in response to IL-8.
Moreover, in the absence of IL-8, transfected cells showed
significantly increased IP accumulation in V247N and Gaqi5
coinfected cells, suggesting that CXCR1 WT and V247N are
coupled to Gai protein and that V247N is capable of constitutively
activating Gai protein (Fig. 6B).
CXCR1 mutant V247N is capable of constitutively
activating Gai
V247N is a robustly expressed mutant coupled to Ga15. Both
CXCR1 WT and V247N mutant are expressed in transfected
COS-7 cells (Fig. 7A) and TSA-201 cells (Fig. 7B). To test whether
V247N is capable of constitutively activating Gai and inhibiting
adenylyl cyclase, CXCR1 WT or V247N mutant were cotrans-
fected with Gai2,G b1, and Gc2 in COS-7 cells. Receptor-
Figure 2. FACS analysis of CXCR1 WT and mutants. HEK 293 cells were transiently transfected with CXCR1 or its mutants. Cells were incubated
with FITC-conjugated mouse anti-human CD181 (CXCR1) antibody. Specificity of signal was confirmed by staining the cells with mouse IgG1 isotype
control. (A) Transfected HEK 293 cell population stained positive for this anti-CXCR1 antibody (M2 region). (B) Fluorescence of positively stained cells
was quantified by FACS (6 SEM, with CXCR1 WT set to 100%).
doi:10.1371/journal.pone.0042765.g002
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common approach to study the action of an inhibitory receptor on
adenylyl cyclase. As shown in Fig. 7C, the addition of IL-8, in the
presence of forskolin, led to a decrease in forskolin-induced cAMP
levels in both CXCR1 WT and V247N mutant-transfected COS-
7 cells by about 35% and 70%, respectively, compared with
forskolin-induced cAMP levels in the absence of IL-8. In V247N-
transfected COS-7 cells, the forskolin-stimulated cAMP produc-
tion was significantly suppressed in the absence of IL-8 compared
with CXCR1 WT transfected cells (P,0.01), suggesting that
V247N constitutively activated Gai-mediated signaling.
In order to further verify the ability of CXCR1 WT and V247N
mutant to inhibit adenylyl cyclase, we utilized a protocol in which
both the CXCR1 receptor and LH receptor were cotransfected.
Cotransfection of the LH receptor, meant to stimulate adenylyl
cyclase via Gas protein, allowed us to induce cAMP accumulation
in those transfected cells. Again, it was found that in the
transfected TSA-201 cells, LH receptor ligand hCG-stimulated
cAMP production was inhibited in response to IL-8 in TSA cells
expressing CXCR1 WT and V247N mutant (Fig. 7B, D). As
shown in Fig. 7D, when CXCR1 WT or V247N is heterologously
expressed in TSA-201 cells, IL-8 inhibited the hCG-stimulated
Figure 3. Binding of
125I-labeled IL-8 to COS-7 cells expressing WT CXCR1 or its mutants. The CXCR1 mutants were transiently transfected
in COS-7 cells. Maximal binding of
125I-IL-8 to CXCR1 WT and mutants (A) and competition binding experiments (B and C) were performed as
described under ‘‘Materials and Methods’’. Competitive binding studies were conducted using
125I-labeled IL-8 and various unlabelled ligands as
described under ‘‘Materials and Methods’’. Representative maximal binding experiments for L128 and V247 mutants are shown in Fig. 3A, performed
in triplicates. Mock was transfected with pSG5 plasmid. Representative competitive binding experiments for L128 and V247 mutants are shown in
Fig. 3(B) and Fig. 3(C), performed in triplicates. Nonspecific binding was determined by adding 250 nM unlabeled IL-8. Curve fitting was done using
GraphPad Prism data analysis program, and the affinity constant (Kd) for CXCR1 mutants is shown in Table 1.
doi:10.1371/journal.pone.0042765.g003
Table 1. Summary of ligand binding assay of CXCR1 WT and
mutants
1.
CXCR1 Location CXCR1 & Bmax Kd (M)
Residue (Baldwin#) Mutants (% of WT)
WT 10060 4.87e-09
Leu 128 TM3, residue 43 L128A 86.862.8 5.35e-10
L128Q 189.4615.5 1.35e-09
L128R 184.163.0 6.86e-10
Val 247 TM6, residue 40 V247A 109.9626.0 5.50e-10
V247F N.D. N.D.
V247N 328.5626.7 3.14e-09
V247Y 126.2621.1 6.93e-10
1Bmax and Kd value were estimated from COS-7 cells ligand binding assay as
described under ‘‘Materials and Methods’’. All assays were done in triplicates.
Values are mean 6 SEM from 3 experiments.
doi:10.1371/journal.pone.0042765.t001
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V247N couple to Gai. In addition, V247N mutant significantly
suppressed hCG-stimulated cAMP accumulation (P,0.01) in the
absence of IL-8, indicating that V247N mutant constitutively
activated Gai.
Chemotaxis mediated by CXCR1 and its mutants
IL-8-induced chemotaxis via CXCR1 requires pertussis toxin-
sensitive Gai protein [51]. To test whether CXCR1 and its
constitutively active mutants can affect cell function, chemotaxis
was measured in cells expressing the CXCR1 or its constitutively
active mutants as well as Gai,G b,G c, and PLCb2. In the absence
of IL-8 cells demonstrated disoriented, non-specific migration. We
did not observe the increase in chemotaxis in non-IL-8-treated
HEK cells expressing these mutants, suggesting that there were no
differences in random migration between CXCR1 WT and
constitutively active mutants. However, in the presence of IL-8,
the cells expressing CXCR1 mutants (V247A and V247N)
displayed enhanced migration than those expressing WT CXCR1,
suggesting that the constitutively active mutants respond to IL-8
above and beyond their constitutive activity. Both CXCR1 and its
constitutively active mutants induced chemotaxis in response to
IL-8 (Fig. 8). Compared to the WT receptor, the constitutively
active mutants demonstrated a 40% and 100% increase in
maximal migration index for V247A and V247N, respectively, in
response to IL-8. PTX blocked chemotaxis mediated by the WT
receptor and constitutively active mutants, suggesting that Gai
signaling was required (Fig. 8).
Discussion
In this study we attempted to identify the role of two amino acid
residues on CXCR1, L128 in TM3 and V247 in TM6, in Gai and
Ga15 coupling. Although our results suggest that both L128 and
V247 are critical amino acid residues involved in Ga15 protein
coupling in transfected COS-7 cells, these two amino acid residues
play distinct roles in G protein coupling. L128, for example, is
involved in the coupling of the receptor to Ga15 and to Gai.
Although mutations in L128 did not affect either its expression or
its binding to IL-8, substitution of this residue caused either the
loss of or dramatically reduced response to IL-8 that resulted from
impaired interaction between the receptor and G proteins. V247,
on the other hand, is associated with maintaining the inactive
conformational structure of CXCR1 so that selective mutation of
residue V247 either transformed the receptor from inactive to
active conformation or stabilized the receptor in its active state,
resulting in the constitutive activation of the receptor.
Detailed functional studies of constitutively active CXCR1
mutations, combined with homology modeling from the active and
inactive rhodopsin as well as H2A receptor crystal structures
serving as templates, led to important insights into the mechanism
of activation, even in the absence of crystal structure of GPCRs in
active state. Our finding that substitutions of V247 in transmem-
brane helix 6 of CXCR1 caused constitutive activation of the Ga15
and Gai signaling pathway may provide new insights into the
specific process by which chemokine binding triggers G protein
activation. The role for IL-8 in CXCR1/CXCR2-mediated
neutrophil recruitment in chronic airway inflammatory diseases,
including COPD and cystic fibrosis, has been delineated. CXCR1
blockade retards viability of breast cancer stem cells and reduces
metastasis [52]. Inhibition of human melanoma growth by
CXCR1 antagonist has been reported [53]. Constitutive activation
of CXCR1 may provide a rapid and sensitive readout for GPCR
signaling and may facilitate screening and/or developing novel IL-
8 antagonists for the treatment of neutrophil-mediated diseases.
Leu3.43 is highly conserved in type A GPCRs and is critical in
activation of several GPCRs [43]. Even when bound to IL-8,
L128A and L128R (obtained by introducing the amino acid Ala or
Arg at TM3.43) either totally impaired their coupling to Ga15 or
dramatically impaired their coupling to Gai despite their ability to
bind to their ligand with high affinity. This implies that L128 is
critical for Ga15 and Gai coupling and that there are discrete steps
in binding and signaling of IL-8 with its receptor. Recently, a two-
site multistep model of how IL-8 binds and activates CXCR1 was
proposed. In this model, CXC motif functions as a conformational
switch that couples Site-I and Site-II interactions for CXCR1.
This coupling is critical for high affinity binding but regulates
activation differently [22]. Our results with mutations at residue
Leu128 support these hypotheses and suggest that this single
amino acid residue may not be involved in ligand binding but may
be involved in the subsequent receptor activation.
Figure 4. CXCR1 mutants coupled to Ga15. (A) Activation of PLCb2
by CXCR1 through Ga15 proteins. COS-7 cells were cotransfected with
equal amounts of cDNA (0.3 mg per well per component) encoding
either pSG5, PLCb2,G a15, CXCR1 wild type (WT), Ga15 plus WT, or PLCb2
plus WT. Inositol phosphates were measured 1 hours after treatment in
the presence (shaded bars) or absence (open bars) of IL-8 (40 nM). Data
are mean 6 SEM of replicate wells. ** P,0.01, Ga15+WT (+IL-8) vs.
Ga15+WT (2IL-8). (B) CXCR1 mutants coupled to Ga15. Basal and IL-8-
stimulated inositol phosphate (IP) accumulation in COS-7 cells
transiently co-transfected with WT (0.3 mg) or mutant CXCR1 (0.3 mg)
and Ga15 (0.3 mg). Data for mutants are summarized from 3–7
experiments, each performed in triplicate, and are expressed as a
percentage of WT CXCR1 baseline determined in parallel. The results are
mean 6 SEM. ** P,0.01, vs.W T + Ga15 (in the absence of IL-8).
doi:10.1371/journal.pone.0042765.g004
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PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e42765Figure 5. Constitutively active mutants of CXCR1. (A) Basal and IL-8-stimulated inositol phosphate (IP) accumulation in COS-7 cells transiently
co-transfected with WT or mutant CXCR1 and Ga15. IP production was determined in detail as described under ‘‘Materials and Methods’’. Data are
mean 6 SEM of replicate wells from a representative experiments performed in triplicate. **, P,0.01, vs.W T + Ga15 (in the absence of IL-8). (B) Calcium
signaling capacity in COS-7 cells transfected with CXCR1 WT and V247N mutant. The increase in intracellular calcium concentration ([Ca
2+]i) in COS-7
cells transfected with Ga15 and CXCR1 WT or V247N mutant was measured using BD calcium assay kit. The cells were stimulated with or without IL-8
(40 nM). Values represent the mean (6 the SEM) increase of [Ca
2+]i (n=4). **, P,0.01, vs.W T + Ga15 (in the absence of IL-8).
doi:10.1371/journal.pone.0042765.g005
Figure 6. CXCR1 and mutants coupled to Gai. (A) COS-7 cells were cotransfected with equal amounts of cDNA (0.1 mg per well per component)
encoding Gai2,G b1,G c2, PLCb2, the WT CXCR1 or its mutants. (B) COS-7 cells were cotransfected with equal amounts of encoding Gaqi5 (qi5) and the
WT CXCR1 or its mutants. The release of inositol phosphates, induced by 40 nM IL-8, was measured 1 hour after the treatment in the presence or
absence of pertussis toxin (PTX) (100 ng/ml) for 18 hrs. Data are mean 6 SEM of replicate wells from a representative experiment. **, P,0.01, vs.W T +
qi5 (in the absence of IL-8).
doi:10.1371/journal.pone.0042765.g006
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identification of CXCR1 mutants with constitutive activity points
to the critical role of this amino acid residue in G protein coupling
and receptor activation. It was proposed that the function of the
inactive, constrained GPCR conformation is to conceal key
cytoplasmic peptide sequences and thus prevent them from
interacting with G proteins [31,54]. Disruption of the constraints
and stabilization of the receptor to an active conformation would
expose the cytoplasmic residues that can bind and activate the
relevant G proteins [31,54]. Thus, amino acid V247 is probably
critical in maintaining CXCR1 in an inactive state. In line with
our findings, it is likely that the constraint of intramolecular bond
stabilizing CXCR1 in an inactive state is disrupted by substitution
of V247 with A or N which would switch the transmembrane
domains to convert the receptor to an active state.
Recent observations in the structure of light-activated rhodopsin
has demonstrated that the movement of cytoplasmic ends of TM5
and TM6 away from the receptor core opens up a cleft in the
center of the helix bundle, thereby allowing the carboxy terminus
of a G protein to bind [55]. Comparison of the agonist- and
inverse agonist-bound b2AR structure also revealed the largest
change to be in TM6, with the outward movement of the
Figure 7. V247N mutant constitutively activates Gai. (A and B) Surface expression of CXCR1 WT and V247N on COS-7 cells (A) and TSA-201 cells
(B). Cells were incubated with mouse anti human CD128a (CXCR1) antibody at 4uC overnight. After washing three times, the cells were incubated
with the secondary antibody (DyLight 549-conjugated goat anti-mouse IgG(H+L)) at RT for 1 hr and counterstained with Dapi. Expression of CXCR1 or
the mutants was observed using a confocal microscope. The pink color represents the surface expression of CXCR1 WT or mutant with Dapi shown in
blue. (C) Inhibition of forskolin-stimulated cAMP production in COS-7 cells. COS-7 cells were transfected with CXCR1 WT or V247N mutant, as well as
Gai2,G b1, and Gc2 expression vector. IL-8 significantly inhibited forskolin-induced stimulation of cAMP formation in transfected cells whereas V247N
mutation inhibited forskolin-induced cAMP levels even in the absence of IL-8. Transfected cells were used for determination of cAMP levels in the
absence (open bars) or in the presence of IL-8 (closed bars). The results shown are representative. (D) Inhibition of hCG-stimulated cAMP accumulation
by V247N mutant. TSA-201 cells were transfected with CXCR1 WT or V247N mutant, as well as LH receptor expression vector. The TSA-201 cells were
pretreated with 0.5 mM IBMX for 30 min followed by treatment with hCG (10
27 M) in the presence or absence of IL-8 (40 nM) for another 30 min.
Following incubation with hCG in the presence or absence of IL-8, cells were lysed and intracellular cAMP measured using a RIA kit as described in
‘‘Experimental Procedures’’. Data presented are the mean 6 SEM for three assays with each condition performed in triplicate.
doi:10.1371/journal.pone.0042765.g007
Figure 8. Chemotaxis assay of CXCR1 WT and its constitutively
active mutants. Chemotaxis assays were performed as described in
Materials and Methods, using HEK293 cells expressing constitutively
active mutants (V247A and V247N) or the WT CXCR1. Data presented
are the mean 6 SEM for three assays with each condition performed in
triplicate. *, P,0.05, V247A vs. WT (+IL-8). **, P,0.01, V247N vs. WT (+IL-
8).
doi:10.1371/journal.pone.0042765.g008
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that are remarkably similar to those observed in active form of
rhodopsin [30,34,55,56,57,58,59]. Beta2AR structure showed
weak interactions between the cytoplasmic ends of TM3 and
TM6 which may account for the relatively high basal activity and
structural instability of the b2AR [60]. TM6 is thought to be one
of the major players in the signaling mechanism and disruption of
its structure would likely affect G protein binding and activation
[29,55,61]. Our study on agonist-independent constitutive activity
of CXCR1 mutants (V247A and V247N) on TM6 and its
signaling provides insights into the process of agonist binding and
activation of GPCRs.
The amino acid residue located at TM6.40 might be critical in
the stabilization of the receptors coupled to various G proteins
such as Gas,G a15,G ai or Gt in the inactive state. Mutations of
TM6.40 in opsin (Met257), TSH receptor (Leu629), muscarinic
receptor (Ile447), and histamine H1 receptor (Ile420) also result in
constitutive activation [39,40,43,44]. Although the particular
residue might be different at this site (Met257 in bovine rhodopsin,
Leu629 in TSHR, Ile447 in the muscarinic receptor, and Val247
in CXCR1), the residue at TM6.40 appears to participate in G
protein coupling and receptor activation as a result of closely
related deviations from regular a-helical structure and similar
tertiary structures. In fact, replacement of TM6.40 in several
different GPCRs (Gt-coupled rhodopsin, Gas-coupled TSHR, and
Gai/Ga15-coupled CXCR1) results in constitutive activity of the
receptors coupled to specific G proteins (Gas,G t,G ai or Ga15).
This suggests that the amino acid residue located at TM6.40 is
critical for the stabilization of the receptors in the inactive state,
which is an intrinsic feature of the receptors and independent of
the G protein type. Structural modification of this single amino
acid residue affects GPCR-G protein interaction and receptor
activation.
Both V247A and V247N demonstrated high efficiency in
coupling to Ga15. Without ligand, mutants V247A and V247N
were stabilized in the active state. However, ligand binding caused
certain responses including elevated IP accumulation, which might
result from conformational changes caused by receptor binding to
its ligand, IL-8. There is strong evidence that GPCRs may exist in
multiple ligand-specific conformational states [31,54]. In the
multistate model, the receptor is proposed to alternate between
multiple active and inactive conformations. A recent publication
on the agonist-bound adenosine A2A receptor structures revealed
an intermediate conformation between the inactive and active
states to support this model [28]. In agreement with this, the
observation that both V247A and V247N CXCR1 mutants with
distinct Kd in this study are constitutively active strongly supports
the concept that more than one active receptor state can exist.
Transmembrane signaling through CXCR1 plays a role in
many neutrophil functions such as chemotaxis [4]. Many of these
signaling pathways have emerged from the studies using cell lines
transfected with receptors or related cellular components. With
regard to our use of COS-7 cells, most of the reconstituted
components, including Gai2,G b1,G a15 and PLCb2 in these cells,
are likely to be found in neutrophils or related myeloid cells where
CXCR1 is expressed [19]. Therefore, both the Ga15- PLCb2 and
the Gai-Gbc-PLCb2 pathways are likely to be active in vivo.I n
addition, chemotactic responses in many leukocytes require
activation of Gai, as indicated by their sensitivity to inhibition
by PTX. In agreement with this, our data indicated that
chemotaxis mediated by CXCR1 or its mutants is completely
abolished in transfected cells pretreated with PTX. Therefore, the
increase in chemotaxis in response to IL-8 observed in cells
expressing constitutively active mutants V247A and V247N can be
attributed to the active signaling through these mutants.
In summary, the two residues in TM3 and TM6 on CXCR1
that correspond to L128 (TM3.43) and V247 (TM6.40), respec-
tively, play distinct roles in receptor activation. Changes in
conformational structure by substituting L128 impaired the
interaction between the receptor and G proteins without affecting
ligand binding. The substitution of V247 impaired the receptor
constraint and stabilized an active conformation. The active
CXCR1 mutants demonstrated increased chemotaxis in response
to IL-8 in a PTX-sensitive manner. These findings regarding the
constitutively active form of CXCR1 may contribute to our
knowledge of the activation of CXCR1 and may be potentially
useful for designing and screening CXCR1-specific antagonists
which may serve as targets for prevention and therapy of certain
neutrophil-mediated inflammatory diseases such as COPD.
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